Posit Science's BrainHQ Training Linked to Reduced Alzheimer’s Biomarker
Event summary
- Posit Science's BrainHQ training reduced beta amyloid biomarkers in the ENACT Study, a randomized controlled trial with 53 participants.
- The study found significant improvements in Aβ42/Aβ40 ratios after 20 hours of speed training, suggesting cognitive training may influence neurodegeneration pathways.
- Results varied by sex, aligning with evidence that men and women respond differently to Alzheimer’s therapies.
- BrainHQ has previously been shown to reduce Alzheimer’s diagnoses by 25% in the ACTIVE Study and rejuvenate acetylcholine production in the INHANCE Study.
The big picture
Posit Science’s findings challenge the decades-long focus on removing plaques and tangles in Alzheimer’s research, suggesting neuroplasticity-based training could offer a new preventive approach. The company’s BrainHQ app has now been linked to three key biomarkers—amyloid reduction, acetylcholine upregulation, and long-term Alzheimer’s risk reduction—positioning it as a potential leader in cognitive resilience interventions.
What we're watching
- Therapeutic Shift
- Whether Posit Science can shift Alzheimer’s research focus from plaque removal to neuroplasticity-based interventions.
- Sex-Specific Responses
- How sex-specific biomarker responses will influence future study designs and treatment protocols.
- Commercialization Pace
- The pace at which BrainHQ can be integrated into mainstream dementia prevention strategies.